A trial of everolimus and BEZ235 for advanced solid tumours

Please note

This trial is no longer recruiting patients. We hope to add results when they are available.

Overview

Cancer types:

All cancer types

Status:

Closed

Phase:

Phase 1

Details

This trial is looking at 2 drugs called everolimus and BEZ235 for advanced including breast cancer and kidney cancer. It is for people who have cancer that has spread to other parts of the body. A solid tumour is any type of cancer apart from or .

Everolimus is a type of biological therapy called an mTOR inhibitor. It stops a protein called mTOR from working properly. BEZ235 is a new drug that blocks the activity of mTOR and another protein called PI3K.

Both mTOR and PI3K are involved in cell growth. Blocking these 2 proteins may help stop cancer cells growing.

The aims of this trial are to

Find the highest doses of everolimus and BEZ235 that you can safely have together
Learn more about the side effects and what happens to the drugs in your body
See how these 2 drugs affect breast cancer and kidney cancer

Recruitment start: 12 January 2012

Recruitment end: 27 November 2013